Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease
JOURNAL OF TRANSLATIONAL MEDICINE
Authors: Cao, Ye-Xuan; Wu, Na-Qiong; Sun, Di; Liu, Hui-Hui; Jin, Jing-Lu; Li, Sha; Guo, Yuan-Lin; Zhu, Cheng-Gang; Gao, Ying; Dong, Qiu-Ting; Liu, Geng; Dong, Qian; Li, Jian-Jun
Abstract
BackgroundPatients with monogenic familial hypercholesterolemia (FH) have high risk for coronary artery disease (CAD). A recent FH Expert Panel suggested that FH was underdiagnosed and undertreated which needs early diagnosis. Moreover, the proportion of DNA-confirmed FH patients hospitalized with very early-onset (35years) CAD remains uncertain.MethodsOne hundred and five patients with age35years and LDL-C3.4mmol/L were tested for 9 genes (LDLR, APOB, PCSK9, APOE, STAP1, LIPA, LDLRAP1, ABCG5/8). Dutch Lipid Clinic Network (DLCN) and Simon Broome (SB) criteria for FH were also performed.ResultsThe prevalence of genetically confirmed FH was 38.1% (n=40) in 105 patients. DLCN categorized 26.7% patients to probable and definite FH while SB identified 17.1% of patients with possible to definite FH. Twenty-five (62.5%) and seventeen (42.5%) patients with pathogenic mutations were undiagnosed according to SB and DLCN criteria. FH variant carriers, especially homozygotes, had significantly higher plasma LDL-C levels. The best LDL-C threshold for genetically confirmed FH was 4.56mmol/L in the present study.ConclusionsFH is really a common cause for very young CAD patients (35years) with a 38.1% of causative mutations in China and best LDL-C threshold for predicting mutations was 4.56mmol/L. The underdiagnostic rate of clinical criteria was around 42.5-62.5%, suggesting that the expanded genetic testing could indeed promote the diagnosis of FH.
Identification of two novel LDLR variants by Next Generation Sequencing
ANNALI DELL ISTITUTO SUPERIORE DI SANITA
Authors: Moffa, Simona; Mazzuccato, Giorgia; De Bonis, Maria; De Paolis, Elisa; Onori, Maria Elisabetta; Pontecorvi, Alfredo; Urbani, Andrea; Giaccari, Andrea; Capoluongo, Ettore; Minucci, Angelo
Abstract
Introduction. Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease characterized by elevated plasma low-density lipoprotein cholesterol (LDL-C). Targeted Next Generation Sequencing (NGS) is a new opportunity to expand the existing pathogenic variants (PVs) spectrum associated to FH. Our aim was to report a diagnostic NGS-based approach to detect variants associated to FH. Methods. We report two patients: a 48-year-old Asian woman, without known history of hypercholesterolemia and a 46-year-old Caucasian man, with childhood hypercholesterolemia. Results. An effective NGS-based pipeline, FH-Devyser kit/Amplicon Suite, beginning from sequencing to data analysis, did not identify known PVs in the LDLR, APOB, APOE, LDLRAP1, STAP1 and PCSK9 genes, but revealed two novel LDLR variants (c.1564A>T, p.Ile522Phe and c.1688C>T, p.Pro563Leu). Discussion and conclusions. This study showed that an effective NGS-based pipeline led to a definitive diagnosis in two FH families, allowing to plan their therapeutic treatment. Although the functional consequence of the two LDLR variants needs to be assessed in vitro, the in silico analysis and high preservation of the two amino acid positions observed in the LDLR protein, across different animal species, suggest that both variants are deleterious.